Agios to Present at Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a prominent entity in cellular metabolism and PK activation therapies for rare diseases, has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled to take place on Monday, June 10, 2024, at 1:20 p.m. ET. Interested parties can view the live presentation via a webcast accessible under the "Events & Presentations" section of the Investors page on the Agios website, www.agios.com. For those unable to attend live, a replay will be made available on the company’s website for two weeks following the presentation.

Agios is renowned for its pioneering efforts in PK activation and is committed to bringing groundbreaking therapies to patients suffering from rare diseases. The company currently markets a first-in-class pyruvate kinase (PK) activator in the United States for adults with PK deficiency, marking the first disease-modifying treatment for this chronic, debilitating form of hemolytic anemia.

The company's expertise spans classical hematology and a deep understanding of cellular metabolism. Agios is advancing a robust pipeline of investigational medicines targeting various rare hematologic disorders including alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia, and phenylketonuria (PKU). Beyond its clinical pipeline, Agios is also developing a preclinical TMPRSS6 siRNA as a potential therapeutic option for polycythemia vera.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!